You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 149 No. 9, September 1989 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL INVESTIGATIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Gastrointestinal Cytomegalovirus Infection in Heart and Heart-Lung Transplant Recipients

Charles S. Kaplan, MD; Eskild A. Petersen, MD; Timothy B. Icenogle, MD; Jack G. Copeland, MD; Hugo V. Villar, MD; Richard Sampliner, MD; Linda Minnich, MS; C. George Ray, MD

Arch Intern Med. 1989;149(9):2095-2100.


Abstract

• Cytomegalovirus (CMV) causes major morbidity in organ transplant recipients. Gastrointestinal disease was the most prominent manifestation of CMV infection in a population of heart and heart-lung transplant patients, with an incidence of 9.9%, compared with pneumonitis (4.0%) and retinitis (0%), and occurred most frequently in CMV-seronegative recipients of organs from CMV-seropositive donors. Clinical manifestations included gastritis (nine patients), gastric ulceration (four patients), duodenitis (three patients), esophagitis (one patient), pyloric perforation (one patient), and colonic hemorrhage (one patient). Patients with gastrointestinal CMV infection were treated with intravenous ganciclovir sodium therapy, 5 mg/kg twice daily, for 2 to 8 weeks, with positive clinical, endoscopic, histologic, and virologic responses. Relapses occurred in four of nine patients who were followed up for a median period of 18 months. Retreatment resulted in healing of endoscopic lesions and in viral clearing. We conclude that early endoscopic evaluation for CMV is indicated in heart and heart-lung transplant patients with gastrointestinal symptoms. This study further suggests that intravenous ganciclovir therapy is effective for the treatment of gastrointestinal CMV in these patients.

(Arch Intern Med. 1989;149:2095-2100)



Author Affiliations

From the Departments of Internal Medicine (Drs Kaplan, Petersen, and Sampliner), Surgery (Drs Icenogle, Copeland, and Villar), and Pathology (Drs Minnich and Ray), University of Arizona College of Medicine, Tucson.


Footnotes

Accepted for publication May 17, 1989.

Reprint requests to Section of Infectious Diseases, University of Arizona Medical Center, 1501 N Campbell Ave, Tucson, AZ 85724 (Dr Petersen).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Multimodal Immunosuppressant Therapy in Steroid-Refractory Common Variable Immunodeficiency Sprue: A Case Report Complicating Cytomegalovirus Infection
Medlicott et al.
INT J SURG PATHOL 2006;14:101-106.
ABSTRACT  

Cytomegalovirus Inclusion Disease Presenting as a Cutaneous Ulcer in AIDS
Husain et al.
Arch Dermatol 1994;130:1315-1316.
ABSTRACT  

Diagnosis and Treatment of Cytomegalovirus Disease in Transplant Patients Based on Gastrointestinal Tract Manifestations
Mayoral et al.
Arch Surg 1991;126:202-206.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1989 American Medical Association. All Rights Reserved.